Mostrando 8 resultados de: 8
Filtros aplicados
Publisher
Pharmacogenomics(3)
Clinical Chemistry and Laboratory Medicine(1)
European Journal of Clinical Pharmacology(1)
Journal of Psychopharmacology(1)
Medicina Clinica(1)
Área temáticas
Farmacología y terapéutica(6)
Enfermedades(4)
Bioquímica(3)
Fisiología humana(3)
Fisiología y materias afines(1)
Objetivos de Desarrollo Sostenible
ODS 3: Salud y bienestar(8)
ODS 10: Reducción de las desigualdades(6)
ODS 17: Alianzas para lograr los objetivos(4)
ODS 9: Industria, innovación e infraestructura(3)
ODS 12: Producción y consumo responsables(2)
Origen
scopus(8)
CYP2D6-1584C>G promoter polymorphism and debrisoquine ultrarapid hydroxylation in healthy volunteers
ArticleAbstract: Background & aim: The CYP2D6-1584C>G polymorphism (rs1080985) has been identified as a major factorPalabras claves:1584C>G, CYP2D6, debrisoquine, Healthy volunteers, ultrarapid metabolismAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Naranjo M.E.G., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopusDetermination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: Application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship
ArticleAbstract: The drug-metabolizing cytochrome P450 (CYP) enzyme CYP2D6 is involved in the metabolism of several cPalabras claves:CYP2D6, debrisoquine, HPLC, Metabolic ratioAutores:Adrián LLerena, Berecz R., Cáceres M.C., Cobaleda J., Dorado P., González I.Fuentes:scopusEffect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes
ArticleAbstract: Sixteen hospitalized white European Spanish psychiatric patients treated with thioridazine alone werPalabras claves:CYP2D6, debrisoquine, Inhibition, ThioridazineAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P., Fernández-Salguero P.Fuentes:scopusQTc interval lengthening and debrisoquine metabolic ratio in psychiatric patients treated with oral haloperidol monotherapy
OtherAbstract:Palabras claves:debrisoquine, Haloperidol, QTcAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P.Fuentes:scopusQTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients
ArticleAbstract: Thioridazine cardiotoxicity has been associated with a prolonged heart-rate corrected QT (QTc) interPalabras claves:CYP2D6, debrisoquine, QTc lengthening, ThioridazineAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P.Fuentes:scopusRelation between CYP2D6 phenotype and genotype and personality in healthy volunteers
ArticleAbstract: Objectives: Our group has previously show that interindividual variability in CYP2D6 hydroxylation cPalabras claves:anxiety, CYP2D6, debrisoquine, KSP, personality, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Alvárez M., Dorado P., González I., Penãs-Lledó E.M., Pérez B.Fuentes:scopusPharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity
ReviewAbstract: Debrisoquine hydroxylation polymorphism is by far the most thoroughly studied genetic polymorphism oPalabras claves:CYP2D6, Cytochrome p450, debrisoquine, PharmacogenomicsAutores:Adrián LLerena, Dorado P., Penãs-Lledó E.M.Fuentes:scopusStudy of debrisoquine hydroxylation polymorphism (CYP2D6) in the Cuban population compared to Spaniards
ArticleAbstract: BACKGROUND AND OBJECTIVE: CYP2D6 metabolic capacity shows genetic polymorphism. Two metabolic phenotPalabras claves:Cubans, CYP2D6, debrisoquine, Hispanics, Interethnic variability, pharmacogenetics, Phenotype, SpaniardsAutores:Adrián LLerena, Alvárez M., Dorado P., González I., Pérez B.Fuentes:scopus